Activation of different Stat5 isoforms contributes to cell-type-restricted signaling in response to interferons.
about
Antiviral actions of interferonsCharacterization of Stat5a and Stat5b homodimers and heterodimers and their association with the glucocortiocoid receptor in mammary cellsActivation of a CrkL-stat5 signaling complex by type I interferons.Stat1 nuclear translocation by nucleolin upon monocyte differentiation.A cytosolic protein-tyrosine phosphatase PTP1B specifically dephosphorylates and deactivates prolactin-activated STAT5a and STAT5b.Functional characterization of interferon regulatory factor 3a (IRF-3a), an alternative splice isoform of IRF-3.Alpha-interferon and its effects on signal transduction pathways.Jak2-Stat5 interactions analyzed in yeast.Signaling via the interferon-alpha receptor in chronic myelogenous leukemia cells.JAK2 tyrosine kinase phosphorylates and is negatively regulated by centrosomal protein Ninein.PDZRN3/LNX3 is a novel target of human papillomavirus type 16 (HPV-16) and HPV-18 E6.Differential expression profiling of spleen microRNAs in response to two distinct type II interferons in Tetraodon nigroviridis.IFN-α/β receptor signaling promotes regulatory T cell development and function under stress conditions.Major differences in the responses of primary human leukocyte subsets to IFN-beta.Effect of JAK Inhibitors on Release of CXCL9, CXCL10 and CXCL11 from Human Airway Epithelial Cells.Stimulated plasmacytoid dendritic cells impair human T-cell developmentDual-Specificity Phosphatase 4 Regulates STAT5 Protein Stability and Helper T Cell Polarization.Essential role of signal transducer and activator of transcription (Stat)5a but not Stat5b for Flt3-dependent signaling.In vivo identification of novel STAT5 target genesSignal transducer and activator of transcription 5 (STAT5) paralog dose governs T cell effector and regulatory functions.STAT5-mediated expression of oncogenic miR-155 in cutaneous T-cell lymphoma.Noncytolytic clearance of sindbis virus infection from neurons by gamma interferon is dependent on Jak/STAT signaling.Potential role of type I interferons in the treatment of pituitary adenomas.Long-term pegylated interferon-alpha and its potential in the treatment of melanomaIL-17: a new actor in IFN-driven systemic autoimmune diseases.Reduction in p48-ISGFgamma levels confers resistance to interferon-alpha2a in MHCC97 cells.Analysis of SOCS-3 promoter responses to interferon gamma.Cell-type and donor-specific transcriptional responses to interferon-alpha. Use of customized gene arrays.Decidual NK cell-derived conditioned medium (dNK-CM) mediates VEGF-C secretion in extravillous cytotrophoblasts.Interferon-γ-induced increases in intestinal epithelial macromolecular permeability requires the Src kinase Fyn.STAT5a activation mediates the epithelial to mesenchymal transition induced by oncogenic RhoAActivation of the p70 S6 kinase and phosphorylation of the 4E-BP1 repressor of mRNA translation by type I interferons.The Stat1 binding motif of the interferon-gamma receptor is sufficient to mediate Stat5 activation and its repression by SOCS3.Activation of STAT5 by IL-4 relies on Janus kinase function but not on receptor tyrosine phosphorylation, and can contribute to both cell proliferation and gene regulation.Interferons activate the p42/44 mitogen-activated protein kinase and JAK-STAT (Janus kinase-signal transducer and activator transcription factor) signalling pathways in hepatocytes: differential regulation by acute ethanol via a protein kinase C-depActivation of signal transducers and activators of transcription 1 and 3 by leukemia inhibitory factor, oncostatin-M, and interferon-gamma in adipocytes.Characterization of the Stat5 protease.Activation of the p38 mitogen-activated protein kinase mediates the suppressive effects of type I interferons and transforming growth factor-beta on normal hematopoiesis.Signal transduction pathways regulated by prolactin and Src result in different conformations of activated Stat5b.P48 is a predictive marker for outcome of postoperative interferon-alpha treatment in patients with hepatitis B virus infection-related hepatocellular carcinoma.
P2860
Q24550676-EFABD33C-474B-4A7F-A390-2BD70C5633E1Q28609047-CED73D30-FD2C-4793-A225-FC731848499AQ30175923-44A731DB-F7FF-47D2-BFB3-E311B11E2840Q33518524-EE77A916-1428-475D-8DD8-FC9B29152F26Q33918209-1EBCF4EA-E880-4310-BF2B-16D1FA357858Q33968523-B4AD7B43-F25D-4B5D-A876-F2152F542E23Q34351416-8F074C7A-1CCC-452F-A9EB-A6EF2BE865D8Q34467000-68874048-2409-4FF0-8BFA-6E26CD40BDECQ34769838-2CBCA1C5-0FE0-4BA4-A0C5-BEE06D5A2CB0Q34968444-5368694F-89E4-4B2A-855A-0EA3E6F00A9FQ34991090-32BB82FE-E0DD-41D8-99D1-61D58A2DAA0AQ35163626-E2CE0041-90B8-4FE5-AD14-AF2CCC101B6EQ35472250-C5E8A640-3D20-43CF-BEC0-124742CF5D64Q35630626-954096FD-131D-4526-8FDC-CC869C8D7327Q35668303-13C2DF00-DF72-42F2-A00E-5A6AB8B6BB5BQ35848849-EBAD7010-47D3-4EB5-9285-C2EA656201A5Q35879703-EB3C4245-B57F-409D-BE43-917158D941DCQ36368800-BD05F35E-0A77-449C-AB0C-B97CDE28EC31Q36740156-1B73F403-3D81-436E-BD95-17091B767F68Q36869017-A5FFDDDE-5E11-44CE-8D04-9032D1EC1B64Q37075919-3FF98355-2EF6-4C74-94BE-51A0FFE8DF7CQ37145314-39CD9E50-E7E9-481F-8A39-9E0C68BF2C0BQ37208454-38862FF7-4D73-4F95-A546-D50DCA50DAFFQ37586916-BD0067CD-FEA4-4801-AE0C-F715FF5A4511Q38040748-0A34C5C0-39F2-4CBF-9D63-550F26692034Q38330577-09783A8B-5171-4E60-A6C8-644DAF7BEBB1Q38345570-2ABD26C1-1B87-4EB5-8162-846B9A00DDADQ38361837-8055951C-29FF-438E-B018-A92B69B7FED3Q39458088-F95FDFAF-6F9E-4562-AFC4-4DCE80E665E2Q39592093-1371706C-52A8-4E7D-84D6-B827657B67FAQ39697053-81F04AB0-96E1-4F16-B302-FF5F18C57193Q40646200-EC595C2F-8AEA-4BF8-805E-3EF5BDE02896Q40778041-D5E567E9-1DAE-4D5A-98DE-7F939AAF5E2CQ40939460-4A5FB7C1-212A-4526-A9C4-4DF98BB381D0Q42004459-BFE9A062-7A12-4CE7-AD36-AECB02DD766DQ42463894-1079C08E-AD8F-4CE4-B2EB-0D9C1F63F0CBQ42811119-DC7472CC-750F-4255-8349-C377DB74B19DQ43843414-721B3048-9B81-4F7B-B0CD-43AD98AB1B15Q44350734-B3D2D481-C79F-4C32-B433-3958181E999BQ45412652-1D7983E7-8032-4E27-AF8A-B3A278673748
P2860
Activation of different Stat5 isoforms contributes to cell-type-restricted signaling in response to interferons.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
1996年论文
@zh
1996年论文
@zh-cn
name
Activation of different Stat5 ...... ng in response to interferons.
@en
type
label
Activation of different Stat5 ...... ng in response to interferons.
@en
prefLabel
Activation of different Stat5 ...... ng in response to interferons.
@en
P2093
P2860
P356
P1476
Activation of different Stat5 ...... ng in response to interferons.
@en
P2093
P2860
P304
P356
10.1128/MCB.16.12.6937
P407
P577
1996-12-01T00:00:00Z